Arthrex DynaNite Staples
ARTHREX, INC. · Decision date Sep 1, 2026
What did the FDA decide?
FDA's September 1, 2026 decision letter records Arthrex DynaNite Staples (K262451) as substantially equivalent (SESE) under 21 CFR 888.3030, Class II, product code JDR, with the Orthopedic review panel. The submission was dated July 16, 2026 and received July 17, 2026; the applicant is Arthrex, Inc. of Naples, Florida. Substantial equivalence is a clearance to market, not premarket approval.
The letter states equivalence to legally marketed predicate devices for the indications for use in the enclosure, but the supplied excerpts do not include that enclosure, so the specific indications, device materials, sizes and any predicate identified in the submission remain unknown. FDA also notes the determination does not establish compliance with other statutory or regulatory requirements, including QMSR obligations. No clinical or performance data are available in the provided text.
The public record lists the review as a Traditional 510(k), not third-party reviewed, not a combination product, and without an authorized predetermined change control plan. The page's last-updated date of October 26, 2026 is later than the decision date and is not explained in the public information.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 1, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262451
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- ARTHREX, INC.
- Product code
- JDR
- Decision code
- SESE
- Decision date
- Sep 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Staple, Fixation, Bone.
- Applicant
- Arthrex, Inc.
- Product code
- JDR
- FDA device class
- 2
FDA decision timeline
K262451 received
Application receipt date recorded by FDA.
K262451 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Arthrex, Inc.
- Headquarters
- Not reported
- Brand website
- arthrex.com
- FDA applicant address
- Naples, FL
Sources and methodology
- Original FDA record: K262451
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records